Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Investing.com - Kamada Ltd. (NASDAQ:KMDA), a $424 million market cap biopharmaceutical company with a "GREAT" InvestingPro Financial Health score of 3.5, received a reiterated Buy rating and $15.00 price target from Benchmark on Thursday following the company’s second-quarter financial results that exceeded analyst expectations.
The biopharmaceutical company reported second-quarter revenues of $44.8 million, representing a 5% increase compared to the same period last year. Earnings per share reached $0.13, up from $0.08 in the prior year. The company maintains strong fundamentals with a healthy current ratio of 4.0 and has delivered impressive year-to-date returns of 24.65%.
Benchmark had previously estimated revenues of $43.5 million and earnings per share of $0.08 for the quarter, which would have been level with the second quarter of 2024.
Revenue growth for Kamada in the second quarter was primarily driven by increased sales of Glassia outside the United States, Varizig in the U.S. market, distribution sales, and royalty income.
Kamada’s management has maintained its revenue forecasts for the full year 2025 while raising EBITDA guidance, factors that contributed to Benchmark’s decision to maintain its Buy rating on the stock. With analyst targets ranging from $11 to $20 and a favorable PEG ratio of 0.82, the stock appears attractively valued relative to its growth prospects.
In other recent news, Kamada Ltd. announced that the U.S. Food and Drug Administration approved its plasma collection center in Houston, Texas. This facility is set to begin commercial sales of normal source plasma, with an expected annual revenue of $8 million to $10 million at full capacity. Additionally, Kamada reported a 17% increase in revenue for the first quarter of 2025, reaching $44 million, aligning with Benchmark’s projections. The company’s earnings per share rose to $0.07 from $0.04 in the same quarter of the previous year. The revenue growth was largely due to a 19% increase in proprietary product sales, including significant contributions from Glassia and Kamrab. Kamada also experienced an uptick in royalty income from Glassia and increased sales of Varizig in North America. Benchmark analysts maintained a Buy rating on Kamada’s stock with a price target of $15.00. These developments highlight Kamada’s continued expansion and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.